EVGN

+ Watchlist + Portfolio

Evogene Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.60
52-Week Range: $0.37 – $1.50
Market Cap: $8.86M
P/E (TTM): —
EPS (TTM): -2.04
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -182.75%
Return on Assets: -37.80%
Gross Margin: -67.59%
Operating Margin: -738.62%
Profit Margin: 0.00%
Current Ratio: 3.57
Debt/Equity: 0.36
Total Debt: $2.10M
Free Cash Flow: $-3.68M
Revenue Growth: -60.70%
Earnings Growth: —
Enterprise Value: $9.98M

EVGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.68M	$2.98M	$5.58M	$3.85M
Cost of Revenue	$909.00K	$1.49M	$2.38M	$4.09M
Gross Profit	$766.00K	$1.49M	$3.20M	-$241.00K
Research & Development	$20.79M	$16.20M	$12.51M	$7.99M
Selling, General & Admin	$10.41M	$7.53M	$8.98M	$5.76M
Operating Expenses	$27.71M	$23.70M	$21.95M	$13.79M
Operating Income	-$26.94M	-$22.20M	-$18.76M	-$14.03M
EBITDA	-$27.01M	-$20.53M	-$13.36M	-$12.20M
Pretax Income	-$29.75M	-$21.95M	-$14.81M	-$13.50M
Income Tax	$90.00K	$19.00K	$9.00K	$1.00K
Net Income	-$26.64M	-$23.88M	-$16.48M	-$8.48M
Diluted EPS	-6.50	-5.20	-2.89	-1.08
Diluted Shares	4.12M	4.57M	5.70M	7.87M

EVGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$28.98M	$20.77M	$15.30M	$12.96M
Receivables	$803.00K	$804.00K	$1.49M	$1.38M
Inventory	$566.00K	$76.00K	$1.82M	$210.00K
Current Assets	$37.75M	$34.47M	$21.59M	$15.63M
Total Assets	$56.13M	$51.10M	$39.86M	$20.05M
Current Liabilities	$5.63M	$6.94M	$18.70M	$3.44M
Long-Term Debt	$10.11M	$10.37M	—	—
Total Debt	$11.93M	$11.51M	$12.87M	$2.20M
Total Liabilities	$21.34M	$22.42M	$25.03M	$8.07M
Retained Earnings	-$233.71M	-$257.59M	-$274.07M	-$282.56M
Shareholders' Equity	$27.93M	$12.05M	-$1.45M	-$82.00K
Working Capital	$32.13M	$27.52M	$2.89M	$12.19M

EVGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.68M	-$21.58M	-$19.70M	-$13.50M
Capital Expenditure	-$1.17M	-$577.00K	-$626.00K	-$135.00K
Free Cash Flow	-$24.85M	-$22.15M	-$20.33M	-$13.64M
Depreciation & Amortisation	$2.58M	$1.30M	$1.38M	$1.14M
Stock-Based Compensation	$1.19M	$1.11M	$1.24M	$654.00K
Investing Cash Flow	$13.27M	-$4.54M	$9.62M	$17.74M
Financing Cash Flow	$9.34M	$18.15M	$4.66M	-$6.60M
Net Change in Cash	-$1.06M	-$7.96M	-$5.42M	-$2.37M

EVGN Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Revenue	$1.61M	$2.44M	$884.00K	$312.00K	$314.00K
Cost of Revenue	$755.00K	$1.61M	$136.00K	$157.00K	$2.28M
Gross Profit	$856.00K	$830.00K	$748.00K	$155.00K	-$1.97M
Research & Development	$3.40M	$3.21M	$2.32M	$1.38M	$1.83M
Selling, General & Admin	$2.02M	$1.94M	$1.50M	$1.50M	$1.20M
Operating Expenses	$5.42M	$4.96M	$3.82M	$2.88M	$3.24M
Operating Income	-$4.57M	-$4.13M	-$3.07M	-$2.72M	-$5.21M
EBITDA	-$2.54M	-$1.95M	-$2.61M	-$1.99M	-$6.46M
Pretax Income	$2.00K	-$2.99M	-$3.53M	-$2.73M	-$5.34M
Income Tax	$7.00K	$0.00	$1.00K	$1.00K	$0.00
Net Income	$427.00K	-$2.59M	-$4.46M	$3.87M	-$5.31M
Diluted EPS	0.06	-0.38	-0.62	0.44	-0.61
Diluted Shares	6.80M	6.80M	7.23M	8.72M	8.72M

EVGN Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Cash & Equivalents	$7.50M	$8.33M	$5.63M	$12.96M	$8.51M
Receivables	$3.29M	$1.79M	$1.99M	$1.38M	$1.70M
Inventory	$2.15M	$1.96M	$2.11M	$210.00K	$175.00K
Current Assets	$16.50M	$28.64M	$20.83M	$15.63M	$14.96M
Total Assets	$34.30M	$33.93M	$26.09M	$20.05M	$17.95M
Current Liabilities	$15.60M	$15.19M	$4.08M	$3.44M	$5.36M
Total Debt	$12.96M	$12.69M	$2.52M	$2.20M	$2.03M
Total Liabilities	$21.91M	$21.55M	$8.83M	$8.07M	$9.96M
Retained Earnings	-$276.66M	-$281.12M	-$277.25M	-$282.56M	-$288.43M
Shareholders' Equity	-$3.65M	-$3.55M	$1.14M	-$82.00K	-$2.54M
Working Capital	$902.00K	$13.45M	$16.76M	$12.19M	$9.60M
Net Debt	$2.88M	$1.70M	—	—	—

EVGN Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Operating Cash Flow	-$5.21M	-$5.18M	-$2.30M	-$3.33M	-$2.69M
Capital Expenditure	-$322.00K	-$122.00K	-$2.00K	-$6.00K	-$6.00K
Free Cash Flow	-$5.53M	-$5.30M	-$2.30M	-$3.34M	-$2.69M
Depreciation & Amortisation	$593.00K	$579.00K	$290.00K	$281.00K	$263.00K
Stock-Based Compensation	$317.00K	$316.00K	$234.00K	$27.00K	$155.00K
Investing Cash Flow	$8.76M	-$2.45M	-$989.00K	$10.91M	$10.26M
Financing Cash Flow	$440.00K	-$159.00K	$4.15M	-$10.34M	-$256.00K
Net Change in Cash	$3.99M	-$7.79M	$859.00K	-$2.76M	$7.32M

Market Snapshot

About

Evogene Ltd. is a computational biology company leveraging big data and artificial intelligence to discover and develop products in multiple life-science based industries. The company's proprietary technology platform uses computational predictive biology and large-scale data analytics to improve the development of seeds, microbes, small molecules, and ag-chemicals. Evogene operates through several subsidiaries targeting different markets including agriculture, industrial applications, and human health. The company's AI-driven approach accelerates product discovery and development while reducing costs and time to market. Headquartered in Israel, Evogene represents a technology-driven approach to life sciences innovation.